share_log
  • Headlines
  • Galectin Therapeutics Presents 3 Abstracts At The American Association For The Study Of Liver Diseases 2024 Liver Meeting

Galectin Therapeutics Presents 3 Abstracts At The American Association For The Study Of Liver Diseases 2024 Liver Meeting

Benzinga ·  Nov 18, 2024 21:01
  • Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal hypertension in MASH cirrhosis
  • Blinded central review system can be effectively set-up for evaluation of esophagogastoduodenoscopy (EGD) in large multi-center trial of patients with MASH cirrhosis and portal hypertension, facilitating utilization of this outcome as a critical endpoint in portal hypertension trials
  • Approximately a third of patients with MASH cirrhosis and portal hypertension (PH) screened for the NAVIGATE trial had the incidental finding of varices on EGD, highlighting the need for screening EGDs in these patients
  • NAVIGATE trial readout on track for December 2024

NORCROSS, Ga., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the presentation of three posters on the ongoing NAVIGATE trial in patients with MASH cirrhosis and portal hypertension at the American Association for the Study of Liver Diseases (AASLD)'s annual meeting 2024 Liver Meeting, being held November 15-19, 2024 in San Diego, California.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment
    Related Stocks Related Stocks
    Symbol Mini Chart Price
    Syros Pharmaceuticals
    SYRS
    -- 0.0995
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.2600
    CNS Pharmaceuticals
    CNSP
    -- 3.1469
    Anebulo Pharmaceuticals
    ANEB
    -- 1.640
    CervoMed
    CRVO
    -- 6.627
    Log In for the Full List
    Investment Course
    Choose stocks based on financial reports
    Quickly master financial season learning guidelines
    When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
    [2025.2] How should NVIDIA's performance be viewed? The key indicator to watch for short-term stock prices is this.
    NVIDIA has been one of the best-performing Technology giants in the US stock market over the past two years, and since 2024, its stock price has experienced sig
    How to view Tesla's performance in January 2025? Pay attention to these four key points.
    It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th